New collaboration to develop orthopaedic adult stem cell therapies
Scientists at the Smith & Nephew Research Centre in York (UK) are launching a collaboration to develop groundbreaking new treatments for bone and joint diseases such as osteoarthritis.
Working in partnership with the Regenerative Medicine Institute (REMEDI) at the National University of Ireland Galway, the Research Centre is developing new therapies using adult bone marrow stem cells to promote the re-growth of healthy cartilage and repair damaged joints. The EUR 6 million ($8.5 million) project is backed by the IDA Ireland, and is being launched in Galway by Ireland's Minister for Enterprise, Trade and Employment, Micheál Martin.
The Smith & Nephew Research Centre has already developed early prototype cell technologies, including the ability to grow human cartilage from adult stem cells. The collaboration with REMEDI, who have extensive expertise in osteoarthritis cartilage repair, shall speed up the process of producing viable new orthopaedic therapies.
The four-year project will be led by James Huckle, Programme Manager for Enabling Technologies at the Smith & Nephew Research Centre, and Professor Frank Barry, Scientific Director of REMEDI an expert in adult stem cell engineering.
Topics
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Novartis drug Afinitor met primary endpoint of Phase III study in women with advanced breast cancer - Trial stopped early after positive interim results showed everolimus plus exemestane extended time without tumor growth
ProteoNic and ORYZON awarded European grant for joint development of therapeutic antibodies against prostate cancer
Category:Pharmaceutical_companies_of_the_United_States
Recombinant and Prophylactic Treatments Boost Global Haemophilia Therapeutics Market - Haemophilia B segment will see high growth over the forecast period, finds Frost & Sullivan
US National Institute on Drug Abuse (NIDA) to Conduct Clinical Study on Biotie's Nepicastat in Cocaine Dependence
Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia
Multi-drug resistant infections rising in children
